Related Experiment Video

Updated: May 6, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Tumor adaptation and resistance to RAF inhibitors

Piro Lito1, Neal Rosen, David B Solit

  • 11] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. [2] Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Nature Medicine
|November 9, 2013
PubMed

Insights

RAF kinase inhibitors show promise for BRAF-mutant melanoma but often lead to temporary effects due to resistance. Understanding these resistance mechanisms is key to developing new therapies and combination strategies for BRAF-mutant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • RAF kinase inhibitors are effective against BRAF-mutant melanoma.
  • Complete tumor regression and long-term efficacy are often limited by drug resistance.

Purpose of the Study:

  • To review current models of RAF inhibitor resistance.
  • To discuss the implications of resistance mechanisms for developing improved therapeutic strategies.

Main Methods:

  • Literature review of resistance mechanisms to RAF inhibitors.
  • Analysis of how resistance impacts treatment of BRAF-mutant tumors.

Main Results:

  • Resistance often involves increased RAF dimers, leading to ERK pathway insensitivity.
  • Alternative resistance mechanisms bypass RAF dependency.
  • Understanding resistance can identify new therapeutic targets.

Conclusions:

  • Mechanisms of RAF inhibitor resistance are diverse and impact treatment outcomes.
  • Further research into resistance is crucial for developing durable therapies for BRAF-mutant melanoma.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K